Synthesis of Pyrrolidine Based Natural or Unnatural Product Derivatives (1): Application of Efficient Asymmetric Induction of C-2 Position in Polysubstituted Pyrrolidines

Hyung Jae Jeong, Ju Man Lee, Min Kyu Kim and Sang-Gyeong Lee*

*Department of Chemistry and Research Institute of Natural Science, Gyeongsang National University, Jinju 660-701, Korea Received January 8, 2002

A novel method for synthesis of polysubstituted pyrrolidines, which possess a C-2 stereocenter, was developed. The strategy involves Grignard addition to the succinimide, derived from L-tartaric acid, followed by stereocontrolled triethylsilane promoted reduction of the resulting cyclic amidols.

J. Heterocyclic Chem., 39, 1019 (2002).

Much recent interest has focussed on the chemistry and biological activity of polysubstituted natural and unnatural pyrrolidines. Members of this *N*-heterocycle family are known to have powerful biological activities. Examples of this are found in the pyrrolidines (-)-anisomycin, which has been used clinically for the treatment of amebic dysentery and trichomonas vaginitis [1], and (+)-preussin, which possesses significant broad-spectrum antibiotic activity against both filamentous fungi and yeasts [2].

Our recent interest in the chemistry and biological activity of polysubstituted natural and unnatural pyrrolidines has led to the development of new methods to prepare polysubstituted-pyrrolidines and -piperidines [3,4]. Our continuing studies in this area required us to devise procedures to prepare a variety of highly functionalized, C-2 substituted pyrrolidines for the purpose of biological evaluation. Specific targets of this effort were *trans*-3,4-dihydroxylated pyrrolidine derivatives, which possess various C-2 substituents. Below, we describe the novel and versatile method we have developed to synthesize these targets.



The strategy involves Grignard addition [5-9] to the succinimide, derived from L-tartaric acid, coupled with stereocontrolled triethylsilane promoted reductive removal of the C-5 hydroxyl group in the cyclic amidol products.

The methodology we have devised for preparation of these targets begins with the conversion of L-tartaric acid (1) to the bis-OTBS blocked *N*-benzyl-succinimide **2**. This is accomplished by treatment of acid **1** with benzylamine followed by diol protection with *t*-butyldimethylsilyl chloride [10] (Scheme 1). Reactions of tartarimide **2** with Grignard reagents afford the corresponding alcohols **3** in moderate to high yields (76 - 91%). The alcohols **3a**, **3b** and **3d** are obtained as *ca*. 1:1 mixtures of separable C-5

epimers (tlc R_f-value differences of *ca.* 0.1), while **3c** is isolated as a single diastereomer. The low stereoselectivity observed in these Grignard addition reactions might be a result of competition between two different modes of chelation control (α and β) and steric effects [11]. In the case of isopropylmagnesium chloride addition, steric effects are more pronounced and, consequently, one diastereomer of **3c** is produced (presumably 5*R*).



Reagents and conditions: a) BnNH₂, TBSCl, imidazole, 70%; b) RMgX, THF, -78 °C to 0 °C. TBS = *tert*-Butyldimethylsilyl.

Removal of the C-5 hydroxyl group was first attempted by using zinc and acetic acidic or the Barton's stannylhydride procedure [12]. However, under these conditions mixtures of diastereomeric products are produced. To overcome this problem, we resorted to the use of the silane reduction procedure [13], since we reasoned that complexation of an oxophilic silane reagent to the C-4 ether oxygen might guide diastereo-controlled hydride delivery to the intermediate *N*-acyliminium ion. Accordingly, addition of triethylsilane to a CH₂Cl₂ solution of **3a** (mixture of diastereomers) at -78 °C and borontrifluoride etherate (BF₃•OEt₂), leads to formation of the reduction product **5a** as a single diastereomer. In addition, reductive dehydroxylation of the cyclic amidols **3b-c**, by using this same procedure, occurs stereoselectively to yield **5b-d** in 85 - 90% yields (Scheme 2). As anticipated [13], the high *trans*-selectivity associated with these reactions most likely results from chelation of the silane to the C-4 oxygen (Figure 1). Consequently, hydride delivery occurs selectively from the top-face at C-5 in the iminium ion to give only *trans* **5**.





Reagents and conditions: a) $BF_3 \cdot OEt_2$, CH_2Cl_2 , -78 °C to 0 °C; b) Et_3SiH , CH_2Cl_2 , -78 °C to 0 °C, 88%; c) (i) $(CH_3)_2S \cdot BH_3$, THF, rt. TBS = *tert*-Butyldimethylsilyl.

The existence of oxygen linked, pentavalent organosilicon species, like that shown in Figure 1, is well documented [14].



Figure 1. The reaction pathway to the enantioselective hydride attack in iminium ion **4**.

The 5-substituted 2-pyrrolidinones 5, prepared by the methodology described above, are converted to 2-substituted 3,4-dihydroxypyrrolidines 8 by the sequence shown in Scheme 2. Removal of the C-2 carbonyl functional group is performed by treatment of 5 with the borane-methyl sulfide complex at room temperature in

THF for 6 hours. Excess reducing agent is quenched prior to work-up by the careful addition of EtOH (5 mL) at -5 °C. With this process pyrrolidines **6** are obtained in moderate yields. The *t*-butyldimethylsilyl blocking group in **6** is removed by treatment with tetrabutylammonium fluoride in THF at room temperature, giving the *N*-benzylpyrrolidines **7**. Finally, hydrogenolytic *N*-benzyl removal, by using Pd(OH)₂ and H₂ (1 atm) in methanol at room temperature, affords the target 2-substituted 3,4dihydroxypyrrolidines **8** in good yields.

Further studies probing the mechanism of the reductive dehydroxylation reaction and the biological properties of the target pyrrolidines are in progress.

EXPERIMENTAL

All non-aqueous reactions were carried out under nitrogen. THF was distilled from Na/benzophenone; methanol was distilled from Mg; methylene chloride was distilled from CaH₂. NMR spectra were measured on a Bruker ARX-300 (500 MHz) spectrometer in CDCl₃ solution used as an internal standard unless otherwise noted (value in ppm); coupling constants are reported in Hz. Ir spectra were taken on a Hitachi 270-50 FT/IR spctrophotometer (λ_{max} , cm⁻¹). Optical rotations were measured on a JASCO DIP -1000 digital polarimeter in a 1-dm cell. The elemental analyses were performed with LECO Micro Carbon Hydrogen Determinator (CHN-800). Mass spectra were obtained by using JEOL JMS-700 spectrophotometer. TLC was run on Merck precoated silica gel plates. Merck silica gel 60 (230-400 mesh) was used for column chromatography. All organic extracts were dried over MgSO₄.

(3*R*,4*R*)-3,4-*bis*[(*tert*-Butyldimethylsiloxy]-1-benzylsuccinimide (2).

A solution of *L*-tartaric acid (9.0 g, 60.0 mmol) and benzylamine (8.05 mL, 78.0 mmol) in xylene (150 mL) was stirred at reflux for 15 hours, cooled to 0 °C and the precipitated solid was collected by filtration. The precipitate was dried *in vacuo* and then used in the next reaction. A solution of the solid (3.0 g, 13.5 mmol) in DMF (15.0 mL) containing imidazole (4.8 g, 68.0 mmol) and *t*-butyldimethylsilyl chloride (6.3 g, 40.0 mmol) was stirred for 12 hours at 25 °C, diluted with water and extracted with CH₂Cl₂. The CH₂Cl₂ extracts were washed with water, dried over MgSO₄ and concentrated *in vacuo* giving a residue that was subjected to flash column chromatography (silica gel, hexane/EtOAc, 30/1, v/v) to afford **2** (5.01 g, 83%) as colorless oil. The spectral data and mp of this substance are identical to those previously reported [8].

Grignard Addition to Succinimide **2**: Synthesis of 5-Substituted 3,4-bis[(*tert*-butyldimethylsiloxy]-5-hydroxy -2-pyrrolidinones (**3**).

A solution of the appropriate Grignard reagent (3.0 *M*, THF, 11.1 mmol, 5 equivalents) in THF was added dropwise to a THF (40 mL) solution of pyrrolidinedione **2** (2.2 mmol) at -78 °C. After stirring at 0 °C for 6 hours, saturated aqueous ammonium chloride was added and the mixture was extracted with CH_2Cl_2 . The CH_2Cl_2 extracts were dried (MgSO₄), filtered and concentrated *in vacuo* giving a residue which was subjected to flash column chromatography (Hexane/EtOAc = 10/1, v/v) to

give the corresponding adducts **3** as oils. Yields, **3a**: 81.7%Ar(0.89 g), **3b**: 76.1% (0.91 g), **3c**: 75.1% (0.82 g), **3d**: 91%Four(1.00 g). R_f values, **3a**-1: 0.22 (Hexane/EtOAc = 10/1, v/v), **3a**-2:Co0.16 (Hexane/EtOAc = 10/1, v/v), **3b**-1: 0.42 (Hexane/EtOAc = 1710)

0.16 (Hexane/EtOAc = 10/1, v/v), **3b**-1: 0.42 (Hexane/EtOAc = 10/1, v/v), **3b**-2: 0.26 (Hexane/EtOAc = 10/1, v/v), **3c**: 0.42 (Hexane/EtOAc = 10/1, v/v), **3d**-1: 0.26 (Hexane/EtOAc = 10/1, v/v), **3d**-2: 0.13 (Hexane/EtOAc = 10/1, v/v).

Compound **3a**-1 has IR (KRS-5): 3520, 3130, 2930, 2860, 1720; ¹H NMR (500 MHz, CDCl₃): δ = 7.03 - 7.12 (m, 5H), 4.38 (d, 1H, J = 15.5 Hz), 4.28 (d, 1H, J = 15.5 Hz), 3.95 (d, 1H, J = 2.80 Hz), 3.62 (d, 1H, J = 2.80 Hz), 3.29 (s, OH), 1.18 (s, 3H), 0.75 (s, 9H), 0.73 (s, 9H), 0.05 (s, 3H), 0.02 (s, 3H), -0.01 (s, 3H), -0.03 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ = 170.9, 138.5, 128.4, 127.5, 127.0, 88.0, 79.1, 76.3, 42.2, 25.7, 25.6, 24.8, 18.1, 18.0, -4.2, -4.3, -4.8, -4.9.

Anal. Calcd for C₂₄H₄₃NO₄Si₂: C, 61.89; H, 9.31; N, 3.01. Found: C, 61.49; H, 9.51; N, 3.21.

Compound **3a**-2 has IR (KRS-5): 3510, 3130, 2950, 2850, 1710; ¹H NMR (500 MHz, CDCl₃): δ = 7.05 - 7.07 (m, 5H), 4.46 (d, 1H, J = 15.7 Hz), 4.16 (d, 1H, J = 15.7 Hz), 3.78 (d, 1H, J = 2.80 Hz), 3.60 (d, 1H, J = 2.80 Hz), 2.81 (s, OH), 1.03 (s, 3H), 0.72 (s, 9H), 0.68 (s, 9H), 0.02 (s, 3H), 0.01 (s, 3H), -0.08 (s, 3H), -0.11 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ = 171.9, 138.2, 128.4, 127.3, 127.0, 92.1, 79.7, 76.3, 42.0, 25.7, 25.6, 20.1, 18.1, 17.9, -4.51, -4.53, -4.8, -5.0.

Anal. Calcd for C₂₄H₄₃NO₄Si₂: C, 61.89; H, 9.31; N, 3.01. Found: C, 61.45; H, 9.50; N, 3.19.

Compound **3b**-1 has IR (KRS-5): 3490, 3030, 2930, 2860, 1710; ¹H NMR (500 MHz, CDCl₃): $\delta = 7.27 - 7.41$ (m, 10H), 4.57 (d, 1H, J = 2.3 Hz), 4.11 (s, 1H), 4.01 (s, 1H), 3.59 (d, 1H, J = 1.68 Hz), 3.27 (d, 1H, J = 13.7 Hz), 2.85 (d, 1H, J = 13.7 Hz), 1.08 (s, 9H), 0.83 (s, 9H), 0.35 (s, 3H), -0.33 (s, 3H), 0.00 (s, 3H), -0.19 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 170.6$, 138.7, 135.9, 131.1, 128.4, 128.0, 127.4, 127.0, 126.7, 90.9, 74.7, 43.7, 42.2, 25.8, 25.5, 18.2, 17.9, -4.4, -5.0, -5.1, -5.8; EIMS (*m*/e): (M⁺) Calcd for C₃₀H₄₇NO₄Si₂, 541.8; found, 541.0; MS *m*/e. 523.8(M-H₂O, 6), 484(60), 466(100), 450(27), 219(68), 91(90).

Anal. Calcd for $C_{30}H_{47}NO_4Si_2$: C, 66.50; H, 8.74; N, 2.58. Found: C, 66.48; H, 8.76; N, 2.60.

Compound **3b**-2 has IR (KRS-5): 3390, 3030, 2930, 2860, 1690; ¹H NMR (500 MHz, CDCl₃): δ = 7.22 -7.33 (m, 10H), 4.69 (d, 1H, J = 15.1 Hz), 4.17 (d, 1H, J = 15.1 Hz), 3.90 (d, 1H, J = 6.5 Hz), 3.49 (d, 1H, J = 6.5 Hz), 3.13 (d, 1H, J = 14.0 Hz), 3.02 (d, 1H, J = 14.0 Hz), 2.51(s, OH), 0.98 (s, 9H), 0.84 (s, 9H), 0.12 (s, 3H), 0.08 (s, 3H), 0.03 (s, 3H), 0.00 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ = 170.6, 138.6, 134.7, 131.1, 128.6, 128.1, 128.0, 127.2, 127.1, 92.0, 83.4, 775.0, 43.1, 39.4, 26.0, 25.8, 18.2, 18.1, -4.2, -4.4, -4.5, -4.8.

Anal. Calcd for C₃₀H₄₇NO₄Si₂: C, 66.50; H, 8.74; N, 2.58. Found: C, 66.49; H, 8.79; N, 2.58.

Compound **3c** has IR (KRS-5): 3480, 3020, 2950, 2860, 1700; ¹H NMR (500 MHz, CDCl₃): $\delta = 7.20 - 7.02$ (m, 10H), 4.28 (s, 1H), 3.85 (d, 1H, J = 0.8 Hz), 3.78 (d, 1H, J = 0.8 Hz), 3.73 (s, OH), 1.98 (m, 1H). 0.79 (d, 3H, J = 6.85 Hz), 0.71 (s, 9H), 0.72 (s, 9H), 0.49 (d, 3H, J = 7.05 Hz), 0.02 (s, 3H), 0.01 (s, 3H), 0.00 (s, 3H), -0.02 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 170.9$, 138.3, 128.6, 127.0, 92.7, 77.7, 74.4, 43.2, 34.0, 25.8, 25.6, 18.1, 17.9, 17.3, 16.6, -4.0, -4.1, -5.1, -5.3; EIMS (*m/e*): (M⁺) Calcd for C₂₆H₄₇NO₄Si₂, 493.83; found, 493.0; MS *m/e*: 478(M-H₂O, 5), 436(100), 418(71), 304(30), 171(82), 91(76).

Anal. Calcd for $C_{26}H_{47}NO_4Si_2$: C, 63.24; H, 9.59; N, 2.84. Found: C, 63.27; H, 9.57; N, 2.86.

Compound **3d**-1 has IR (KRS-5): 3530, 3130, 2950, 2860, 1710; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.99 - 7.15$ (m, 10H), 4.51 (d, 1H, J = 15.0 Hz), 3.89 (d, 1H, J = 2.7 Hz), 3.71 (d, 1H, J = 15.0 Hz), 3.67 (d, 1H, J = 2.7 Hz), 3.01 (s, OH), 0.70 (s, 9H), 0.49 (s, 9H), -0.01 (s, 3H), -0.20 (s, 3H), -0.36 (s, 3H), -0.54 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 172.9$, 138.0, 136.1, 128.6, 128.4, 128.3, 128.2, 127.9, 127.8, 127.1, 95.1, 81.2, 76.8, 44.2, 25.6, 18.0, -4.5, -5.0, -5.2, -5.4.

Anal. Calcd for C₃₀H₄₇NO₄Si₂: C, 61.89; H, 9.31; N, 3.01. Found: C, 61.49; H, 9.51; N, 3.21.

Compound **3d**-2 has IR (KRS-5): 3510, 3120, 2930, 2860, 1720; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.91 - 7.26$ (m, 10H), 4.41 (d, 1H, J = 14.9 Hz), 4.18 (d, 1H, J = 5.5 Hz), 3.97 (d, 1H, J = 5.5 Hz), 3.82 (s, OH), 3.74 (d, 1H, J = 14.9 Hz), 0.77 (s, 9H), 0.64 (s, 9H), -0.11 (s, 3H), -0.00 (s, 3H), -0.12 (s, 3H), -0.61 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 171.9$, 139.9, 137.8, 128.6, 128.4, 128.1, 127.2, 127.0, 89.4, 82.2, 76.1, 44.3, 25.8, 25.6, 18.3, 17.8, -4.0, -4.4, -4.8, -5.4.

Anal. Calcd for C₃₀H₄₇NO₄Si₂: C, 61.89; H, 9.31; N, 3.01. Found: C, 61.48; H, 9.49; N, 3.19.

Reaction of Alcohol **3** with Boron Trifluoride Diethyl Etherate and Triethylsilane Reagents: Synthesis of (3R, 4R, 5S)-3,4-Bis[(*tert*-butyldimethylsilyl)oxy]-5-(alkyl or -aryl)-1-benzyl-2-pyrrolidinone (**5**).

To a solution of the diasteremeric mixture alcohol (3, 2.14 mmol) in CH₂Cl₂ (30 ml), a solution of BF₃•OEt₂ (0.39 ml, 3.22 mmol, 1.5 equivalent) and Et₃SiH (3.53 ml. 21.4 mmol) was added under N₂, and the reaction mixture was kept at -78 °C for 6 hours then the temperature was slowly increased to 0 °C. After that, the reaction mixture was stirred for 12 hours at 0 °C and the excess BF₃•OEt₂ and Et₃SiH were quenched with saturated NaHCO₃ (4 ml) at 0 °C, extracted with CH₂Cl₂ (40 ml x 4), washed with water (30 ml x 3), dried over MgSO₄ and filtered through a glass filter. After the solvent was evaporated under reduced pressure, the residue was purified by flash column chromatography (*n*-hexane/EtOAc = 30/1) to give the corresponding **5** as oils. Yields, **5a**: 88.0% (0. 85 g), **5b**: 83% (0.93 g), **5c**: 88% (0.90 g), 5d: 87% (0.95 g).

Compound **5a** has the following physical and spectral properties: $[\alpha] {}^{23} {}_{D} {}^{-1.09^{\circ}}$ (*c* 2.7, CHCl₃); IR (KRS-5): 3020, 2950, 2860, 1710; {}^{1}H NMR (500 MHz, CDCl₃): $\delta = 7.11 {}^{-7.11}$ (m, 5H), 4.92 (d, 1H, J = 15.3 Hz), 4.01 (d, 1H, J = 4.2 Hz), 3.87 (d, 1H, J = 15.3 Hz), 3.63 (t, 1H, J = 4.2 Hz), 3.09 {}^{-3.11} (m, 1H), 1.11 (d, 1H, J = 6.6 Hz), 0.85 (s, 9H), 0.75 (s, 9H), 0.11 (s, 3H), 0.08 (s, 3H), 0.07 (s, 3H), -0.91 (s, 3H); {}^{1}3C NMR (125 MHz, CDCl₃): $\delta = 171.7$, 136.5, 128.6, 127.8, 127.4, 79.8, 78.1, 58.4, 43.5, 25.9, 25.8, 25.7, 18.2, 17.8, 16.9, -4.1, -4.3, -4.5, -4.7.

Anal. Calcd for $C_{24}H_{43}NO_3Si_2$: C, 64.09; H, 9.64; N, 3.11. Found: C, 63.97; H, 9.61; N, 3.21.

Compound **5b** has the following physical and spectral properties: $[\alpha] {}^{23} {}_{D} 6.30^{\circ}$ (*c* 1.3, CHCl₃); IR (KRS-5): 3020, 2950, 2860, 1710; ¹H NMR (500 MHz, CDCl₃): $\delta = 7.32 - 7.57$ (m, 10H), 5.36 (d, 1H, J = 15.3 Hz), 4.23 (s, 1H), 4.19 (d, 1H, J = 14.9 Hz), 4.07 (s, 1H), 3.59 (dd, 1H, J = 4.9 Hz, J = 4.9 Hz), 3.29 (dd, 1H, J = 4.9 Hz, J = 4.9 Hz), 3.00 (1H, dd, J = 13.4 Hz, J = 13.4 Hz), 1.25 (s, 9H), 0.96 (s, 9H), 0.49 (d, 6H, J = 5.1 Hz), -0.01 (s, 3H), -0.20 (s, 3H); {}^{13}C NMR (125 MHz, CDCl₃): $\delta = 172.5, 137.6, 136.2, 129.3, 128.7, 128.5, 128.1, 127.4, 126.7, 128.5, 128.1, 127.4, 128.5, 128.1, 127.4, 128.5, 128.1, 127.4, 128.5, 128.1, 127.4, 128.5, 128.1, 127.4, 128.5, 128.1, 127.4, 128.5, 128.1, 127.4, 128.5, 128.1, 127.4, 128.5, 128.1, 127.4, 128.5, 128.1, 128.5, 128.1, 128.5, 128.1, 128.5, 128.1, 128.5, 128.5, 128.1, 128.5, 1$

78.4, 77.2, 74.0, 67.4, 44.2, 37.7, 28.5, 18.1, 17.6, -4.4, -5.1, -5.4, -5.5. EIMS (*m/e*): (M⁺) Calcd for $C_{30}H_{47}NO_3Si_2$, 525.87; found, 525.0; MS *m/e*: 510(6), 468(100), 406(15), 91(29).

Anal. Calcd for $C_{30}H_{47}NO_3Si_2$: C, 68.52; H, 9.01; N, 2.66. Found: C, 68.53; H, 9.03; N, 2.68.

Compound **5c** has the following physical and spectral properties: $[\alpha]^{23}_{D} 7.37^{\circ}$ (*c* 0.8, CHCl₃); IR (KRS-5); 3020, 2920, 2850, 1700; ¹H NMR (500 MHz, CDCl₃): δ = 7.02 - 6.99 (m, 5H), 4.92 (d, 1H, J = 15.3 Hz), 3.83 (d, 1H, J = 0.9Hz), 3.73 (d, 1H, J = 15.3Hz), 3.65 (s, 1H), 2.91 (d, 1H, J = 4.7 Hz), 0.82 (s, 1H), 0.73 (d, 3H, J = 7.1 Hz), 0.62 (d, 3H, J = 7.0 Hz), 0.62 (d, 3H, J = 6.95 Hz), 0.71 (s, 9H), 0.63 (s, 9H), 0.01 (s, 3H), 0.00 (s, 3H), -0.01 (s, 3H), -0.20 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ = 140.8, 128.2, 128.0, 126.5, 80.6, 78.9, 78.3, 60.2, 59.9, 29.2, 25.8, 25.7, 20.2, 18.8, 17.9, 17.8, -4.1, -4.5, -4.7, -4.8; EIMS (*m/e*): (M⁺) Calcd for C₂₆H₄₇NO₃Si₂, 477.83; found, 477.0; MS *m/e*: 462(6), 420(100), 288(8), 199(39), 91(31), 73(21).

Anal. Calcd for C₂₆H₄₇NO₃Si₂: C, 65.35; H, 9.91; N, 2.93. Found: C, 65.37; H, 9.93; N, 2.96.

Compound **5d** has the following physical and spectral properties: $[\alpha]^{23}_{D} 2.13^{\circ}$ (*c* 1.67, CHCl₃); IR (KRS-5) 3050, 2930, 2860, 1710; ¹H NMR (500 MHz, CDCl₃): $\delta = 6.81 - 7.17$ (m, 10H), 4.89 (d, 1H, J = 14.8 Hz), 4.05 (d, 1H, J = 5.4 Hz), 3.87 (t, 1H, J = 5.1 Hz), 3.83 (d, 1H, J = 5.1 Hz), 3.27 (d, 1H, J = 14.8 Hz), 0.76 (s, 9H0, 0.59 (s, 9H), 0.11 (s, 3H), 0.01 (s, 3H), -0.24 (s, 3H), -0.61 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 172.1$, 137.3, 136.4, 129.2, 129.0, 128.9, 128.8, 127.9, 82.3, 777.2, 66.6, 44.4, 26.3, 26.2, 26.0, 25.9, 18.7, 18.1, -3.6, -4.0, -4.2, -4.9.

Anal. Calcd for $C_{29}H_{45}NO_3Si_2$: C, 68.05; H, 8.86; N, 2.74. Found: C, 68.37; H, 8.61; N, 2.51.

Reduction of Lactam **5** with Borane-methyl Sulfide Complex: Synthesis of (2*S*,3*R*,4*R*)-3,4-Bis[(*tert*-butyldimethylsilyl)oxy]-2-(alkyl or -aryl)1-benzylpyrrolidine (**6**).

A solution of Me₂S•BH₃ (2 *M* in THF, 3.3 ml, 3.22 mmol) was added under N₂ to a solution of the lactam **5** (1.9 mmol) in THF (30 ml). The reaction mixture was kept at room temperature for 2 hours and refluxed for 1 hour. The excess Me₂S·BH₃ was quenched with EtOH (2 ml) at -5 °C. After the solvent was evaporated under reduced pressure, the residue was dissolved in EtOH (20 ml) and heated at reflux for 2 hours. The reaction mixture was cooled to room temperature and treated with saturated NaHCO₃, extracted with CH₂Cl₂ (30 ml x 3). The collected CH₂Cl₂ was washed with water, dried over MgSO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography (*n*-hexane/EtOAc = 30/1) to give corresponding compounds **6** as oils. Yields, **6a**: 88.0% (0.58 g), **6b**: 73% (0.71 g), **6c**: 82.8% (0.48 g), **6d**: 80% (0.76 g).

Compound **6a** has the following physical and spectral properties: [α] ²³ _D 13.55° (*c* 2.67, CHCl₃); IR (KRS-5): 3020, 2950, 2850, 1460; ¹H NMR (500 MHz, CDCl₃): δ = 7.13 - 7.23 (m, 5H), 3.88 (d, 1H, J = 13.8 Hz), 3.85 (dd, 1H, J = 3.1 Hz, J = 6.9 Hz), 3.61 (dd, 1H, J = 3.4 Hz, J = 6.4 Hz), 3.12 (d, 1H, J = 13.48 Hz), 2.64 (dd, 1H, J = 2.5 Hz, J = 10.4 Hz), 2.43 (dd, 1H, J = 6.8 Hz, J = 10.35 Hz), 2.64 - 2.66 (m, 1H), 1.10 (d, 1H, J = 6.3 Hz), 0.81 (s, 9H), 0.77 (s, 9H), 0.00 (s, 6H), -0.08 (s, 3H), -0.14 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ = 139.1, 128.7, 128.0, 126.7, 86.3, 77.8, 76.8, 65.3, 59.9, 57.7, 25.9, 17.9, 16.8, -4.1, -4.3, -4.4, -4.6; EIMS (*m/e*): (M⁺) Calcd for C₃₀H₄₇NO₃Si₂, 435.79; found, 435.0; MS *m/e*: 420(50), 401(5), 378(15), 147(100), 91(53), 73(35).

Anal. Calcd for $C_{24}H_{45}NO_2Si_2$: C, 66.15; H, 10.41; N, 3.21. Found: C, 66.16; H, 10.43; N, 3.24.

Compound **6b** has the following physical and spectral properties: $[\alpha]^{23}_{D}$ 3.67° (*c* 2.60, CHCl₃); IR (KRS-5): 3020, 2950, 2850, 1460; ¹H NMR (500 MHz, CDCl₃): δ = 7.07 - 7.29 (m, 10H), 3.86 (d, 1H, J = 4.2 Hz), 3.80 (d, 1H, J = 13.4Hz), 3.76 (s, 1H), 3.47 (d, 1H, J = 13.4Hz), 2.73 - 2.82 (m, 4H), 2.66 (dd, 1H, J = 4.3Hz, J = 10.0 Hz), 0.87 (s, 9H), 0.73 (s, 9H), 0.00 (s, 3H), -0.04 (s, 3H), -0.22 (s, 3H), -0.34 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ = 140.4, 140.2, 129.6, 129.4, 128.7, 128.3, 128.1, 128.0, 126.6, 125.8, 125.7, 81.7, 78.6, 73.9, 39.6, 26.0, 25.9, 25.7, 18.0, 17.7, 0.0, -4.6, -4.7, -4.9, -5.1.

Anal. Calcd for C₃₀H₄₉NO₂Si₂: C, 70.39; H, 9.65; N, 2.74. Found: C, 70.37; H, 9.61; N, 2.71.

Compound **6c** has the following physical and spectral properties: $[\alpha]^{23}_{D}$ 5.73° (*c* 0.30, CHCl₃); IR (KRS-5): 3020, 2940, 2860, 1450; ¹H NMR (500 MHz, CDCl₃): δ = 7.18 - 7.37 (m, 5H), 4.05 (d, 1H, J = 13.8 Hz), 3.88 (s, 1H), 3.83 (d, 1H, J = 3.9 Hz), 3.33 (d, 1H, J = 13.8 Hz), 2.75 (d, 1H, J = 10.2 Hz), 2.45 (dd, 1H, J = 4.1 Hz, J = 9.9 Hz), 2.31 (dd, 1H, J = 2.4 Hz, J = 5.9 Hz), 1.94 - 1.95 (m, 1H), 1.01 (d, 3H, J = 6.8 Hz), 0.97 (d, 3H, J = 6.8 Hz), 0.06 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ = 140.8, 128.2, 128.0, 126.5, 80.6, 78.9, 78.3, 60.2, 59.9, 29.2, 25.8, 25.7, 20.2, 18.8, 17.9, 17.8, -4.1, -4.5, -4.7, -4.8.

Anal. Calcd for C₂₆H₄₉NO₂Si₂: C, 67.32; H, 10.65; N, 3.02. Found: C, 67.37; H, 10.35; N, 3.05.

Compound **6d** has the following physical and spectral properties: $[\alpha]^{23}_{D}$ 12.19° (*c* 2.87, CHCl₃); IR (KRS-5): 3060, 3020, 2930, 2850, 1460; ¹H NMR (500 MHz, CDCl₃): $\delta = 7.17 - 7.49$ (m, 10H), 3.93 - 4.05 (m, 1H), 3.93 (dd, 1H, J = 3.7 Hz, J = 6.7 Hz), 3.76 (d, 1H, J = 13.7 Hz), 3.28 (d, 1H, J = 6.7 Hz), 3.06 (d, 1H, J = 13.7 Hz), 2.91 (dd, 1H, J = 2.5 Hz, J = 10.3 Hz), 2.60 (dd, 1H, J = 6.9 Hz, J = 10.2 Hz), 0.86 (s, 9H), 0.86 (s, 9H), 0.01 (s, 3H), -0.04 (s, 3H), -0.15 (s, 3H), -0.45 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 141.0$, 139.2, 128.6, 128.3, 128.2, 128.0, 127.4, 126.6, 87.6, 77.8, 75.6, 59.3, 57.6, 25.9, 25.8, 17.9, 17.8, -4.4, -4.5, -4.5, -5.3.

Anal. Calcd for $C_{29}H_{47}NO_2Si_2$: C, 69.96; H, 9.52; N, 2.81. Found: C, 69.97; H, 9.53; N, 2.84.

Deprotection of the TBDMS Group of **6** with Tetrabutylammonium Fluoride: Synthesis of (2S, 3R, 4R)-3,4-Dihydroxy-2-(alkyl or aryl)-1-benzylpyrrolidine (**7**).

To a solution of the *O*-TBDMS (*tert*-butyldimethylsilyl) protected **6** (2.0 mmol) in THF (20 ml) was added TBAF (tetrabutylammonium fluoride) (1.0 mol in THF, 4 ml) at room temperature and stirred for 1 hour. The reaction was quenched with water (10 ml) and extracted with EtOAc (30 ml x 3). The collected EtOAc was washed with water, dried over MgSO₄, and concentrated under reduced pressure. The residue was purified by flash column chromatography (*n*-hexane/EtOAc = 3/1) to give corresponding compounds 7 as oils. Yields, **7a**: 93.0% (0. 39 g), **7b**: 70% (0.39 g), **7c**: 86% (0.21 g), **7d**: 77% (0.40 g).

Compound **7a** has the following physical and spectral properties: [α] ²³ _D 20.62° (*c* 0.20, CHCl₃); IR (KRS-5): 3370, 3230, 3020, 2960, 2860, 2800, 1630, 1450; ¹H NMR (500 MHz, acetone-d₆): δ = 7.13 - 7.49 (m, 5H), 3.98 (d, 1H, J = 13.2 Hz), 3.89 - 3.91 (m, 1H), 3.59 - 3.61 (m, 1H), 3.10 (d, 1H, J = 13.2 Hz), 2.71 (dd, 1H, J = 1.9 Hz, J = 10.3 Hz), 2.47 (dd, 1H, J = 6.9

Hz, J = 10.32 Hz), 2.27 - 2.30 (m, 1H), 2.04 - 2.08 (m, 1H), 1.23 (d, 3H, J = 6.0 Hz): ¹³C NMR (125 MHz, acetone-d₆): δ = 140.4, 129.5, 128.9, 127.5, 86.4, 77.1, 66.8, 61.0, 58.5, 17.3.

Anal. Calcd for $C_{12}H_{17}NO_2$: C, 69.54; H, 8.27; N, 6.76. Found: C, 69.58; H, 8.29; N, 6.73.

Compound **7b** has the following physical and spectral properties: $[\alpha] {}^{23} {}_{\rm D} 7.64^{\circ}$ (*c* 0.07, CHCl₃). IR (KRS-5): 3360, 3060, 3020, 2920, 2810, 1490; ¹H NMR (500 MHz, acetone-d₆): $\delta = 7.16 - 7.35$ (m, 10H), 4.02 (d, 1H, J = 13.2 Hz), 3.90 - 3.91 (m, 2H), 3.83 - 3.84 (m, 1H), 3.45 - 3.73 (broad s, 1H), 3.28 (d, 1H, J = 13.2 Hz), 2.96 - 2.98 (m, 2H), 2.74 - 2.76 (m, 2H), 2.59 (dd, 1H, J = 6.0 Hz, J = 10.2 Hz); ¹³C NMR (125 MHz, acetone-d₆): $\delta = 206.8, 206.6, 206.5, 141.2, 141.1, 131.0, 129.9, 129.3, 129.2, 127.9, 127.1, 82.9, 77.7, 73.5, 60.7, 60.1, 39.5.$

Anal. Calcd for C₁₈H₂₁NO₂: C, 76.29; H, 7.47; N, 4.94. Found: C, 76.28; H, 7.49; N, 4.99.

Compound **7c** has the following physical and spectral properties: $[\alpha]^{23}$ _D 14.60° (*c* 1.67, CHCl₃); IR (KRS-5): 3390, 3020, 2950, 2790, 1450; ¹H NMR (500MHz, CDCl₃): δ = 7.22 -7.32 (m, 10H), 4.01 (d, 1H, J = 13.2 Hz), 3.91 (d, 1H, J = 4.1 Hz), 3.76 (d, 1H, J = 3.9 Hz), 3.19 (d, 1H, J = 10.3 Hz), 2.47 (dd, 1H, J = 4.0 Hz, J = 10.3 Hz), 2.38 (broad s, 2OH), 2.22 (t, 1H, J = 4.2 Hz), 2.03 - 2.11 (m, 1H), 1.05 (d, 3H, J = 6.7 Hz), 0.09 (d, 3H, J = 6.8 Hz); ¹³C NMR (125MHz, CDCl₃): δ = 138.8, 128.7, 128.3, 127.0, 78.6, 76.6, 76.5, 59.0, 57.6, 26.8, 19.8, 16.5; EIMS (*m*/e): (M⁺) Calcd. for C₁₄H₂₁NO₂, 235.16; found, 235.0; MS *m*/e: 204(9), 192(75), 160(5), 91(100), 65(12).

Anal. Calcd for C₁₄H₂₁NO₂: C, 71.46; H, 8.99; N, 5.95. Found: C, 71.48; H, 8.97; N, 5.97.

Compound **7d** has the following physical and spectral properties: [α] ²³ _D 11.70° (*c* 0.20, CHCl₃); IR (KRS-5): 3410, 3030, 2950, 2820, 1450; ¹H NMR (500 MHz, acetone-d₆): δ = 7.19 - 7.55 (m, 10H), 5.21 (broad s, 1 OH), 4.04 - 4.05 (m, 1H), 3.89 - 3.91 (m, 1H), 3.75 (d, 1H, J = 6.8 Hz), 3.29 (d, 1H, J = 13.4 Hz), 3.06 (d, 1H, J = 13.4 Hz), 2.93 (d, 1H, J = 10.3 Hz), 2.91 -2.99 (s, OH), 2.63 (dd, 1H, J = 6.8 Hz, J = 10.3 Hz); ¹³C NMR (125 MHz, acetone-d₆): δ = 206.3, 206.2, 142.7, 140.1, 130.2, 129.3, 129.2, 129.1, 128.9, 128.8, 128.7, 128.1, 127.6, 87.9, 77.5, 77.3, 60.5, 58.5.

Anal. Calcd for $C_{17}H_{19}NO_2$: C, 75.81; H, 7.11; N, 5.20. Found: C, 75.77; H, 7.23; N, 5.31.

Deprotection of the Benzyl group of **7** with Palladium Hydroxide/Hydrogen: Synthesis of (2S, 3R, 4R)-3,4-Dihydroxy-2-(alkyl or aryl)-pyrrolidine (**8**).

To a solution of the *N*-benzyl protected **7** (1.1 mmol) in MeOH was added Pd(OH)₂ (0.1 g) under H₂ pressure (1 atm) at room temperature. After 12 hours, the inorganic salt was filtered through a Celite fitted glass filter and rinsed with MeOH. The MeOH solution was acidfied with HCl (2 *N*) at 0 °C. The solvents were evaporated under reduced pressure, and the residue was dissolved in MeOH. To the MeOH solution, to absorb the product, was added Dowex 50W-X8 (0.3 g) and was stirred for 30 minutes. The solvents were evaporated, and the mixture of Dowex 50W-X8 and product were subjected to column chromatography and purified by elution with ammonia water to give corresponding compounds **8** as solids. Yields, **8a**: 64% (82 mg), **8b**: 95.0% (200 mg), **8c**: 90% (140 mg), **8d**: 90% (240 mg).

Compound **8a** has the following physical and spectral properties: $[\alpha] {}^{23}D -7.13^{\circ}$ (*c* 1.08, H₂O); ¹H NMR (500 MHz, D₂O): $\delta = 4.04 - 4.71$ (m, 1H), 3.53 - 3.55 (m, 1H), 3.02 (dd, 1H,

J = 6.3 Hz, J = 12.5 Hz), 2.81 (t, 1H, J = 6.5 Hz), 2.74 (dd, 1H, J = 3.5 Hz, J = 12.5 Hz), 1.15 (d, 3H, J = 6.6 Hz); ¹³C NMR (125 MHz, D₂O): δ = 83.7, 77.7, 59.9, 50.8, 17.4; EIMS (*m/e*): (M⁺) Calcd for C₁₄H₂₁NO₂, 117.15; found, 117.15; MS *m/e*: 99(16), 82(7), 71(8), 57(100), 56(33).

Anal. Calcd for $C_5H_{11}NO_2$: C, 51.26; H, 9.46; N, 11.96. Found: C, 51.28; H, 9.47; N, 11.97.

Compound **8b** has the following physical and spectral properties: [α] ²³ _D 45.48° (*c* 0.35, H₂O); ¹H NMR (500 MHz, D₂O): δ = 7.12 - 7.24 (m, 5H), 4.01 - 4.03 (m, 1H), 3.72 (dd, 1H, J = 5.2 Hz, J = 5.2 Hz), 3.14 - 3.16 (m, 1H), 3.04 (dd, 1H, J = 5.7 Hz), 2.94 (dd, 1H, J = 6.3 Hz, J = 6.3 Hz), 2.83 (dd, 1H, J = 3.1 Hz, J = 8.0 Hz), 2.71 (dd, 1H, J = 8.7 Hz, J = 8.7 Hz); ¹³C NMR (125 MHz, D₂O): δ = 138.24, 129.8, 129.5, 129.3, 129.1, 127.4, 80.9, 76.9, 66.2, 50.8, 38.1; EIMS (*m*/*e*): (M⁺) Calcd. for C₁₄H₁₅NO₂, 193.11; found, 191.0(M-2); MS *m*/*e*: 148(10), 132(13), 102(M-Bz, 100), 91(tropylium, 38), 77(14).

Anal. Calcd for $C_{11}H_{15}NO_2$: C, 68.37; H, 7.82; N, 7.25. Found: C, 68.47; H, 7.83; N, 7.19.

Compound **8c** has the following physical and spectral properties: $[\alpha]_{D}^{23} = 0.03^{\circ}$ (*c* 0.20, H₂O); ¹H NMR (500 MHz, D₂O): $\delta = 4.08 - 4.10$ (m, 1H), 3.82 - 3.83 (m, 1H), 2.98 (dd, 1H, J = 4.8 Hz, J = 12.5 Hz), 2.87 (dd, 1H, J = 2.4 Hz, J = 12.5 Hz), 2.53 (dd, 1H, J = 5.3 Hz, J = 8.1 Hz), 1.72 - 1.76 (m, 1H), 0.98 (d, 3H, J = 6.7 Hz), 0.95 (d, 3H, J = 6.7 Hz); ¹³C NMR (125 MHz, D₂O): $\delta = 81.1$, 78.5, 51.2, 31.2, 19.6, 19.3; EIMS (*m*/*e*): (M⁺) Calcd for C₇H₁₅NO₂, 145.11; found, 145.0; MS *m*/*e*: 145(45) 128(52), 116(38), 102(80), 72(100), 56(64).

Anal. Calcd for C₇H₁₅NO₂: C, 57.90; H, 10.41; N, 9.65. Found: C, 57.92; H, 10.43; N, 9.67.

Compound **8d** has the following physical and spectral properties: $[\alpha]_{23} {}_{D}$ -2.25° (*c* 0.10, H₂O); ¹H NMR (500 MHz, D₂O): δ = 7.27 - 7.39 (m, 5H), 3.82 - 3.86 (m, 1H), 3.53 - 3.56 (m, 1H), 2.90 (dd, 1H, J = 4.8 Hz, J = 4.8 Hz), 2.73 - 2.83 (m, 3H); ¹³C NMR (125 MHz, D₂O): δ = 139.0, 129.8, 129.0, 126.9, 73.9, 73.7, 43.3, 39.1; EIMS (*m/e*): (M⁺) Calcd. for C₁₄H₂₁NO₂,193.24; found, 193.0; MS *m/e*: 163(10), 134(17), 103(23), 91(100), 65(23).

Anal. Calcd for $C_{10}H_{13}NO_2$: C, 67.02; H, 7.31; N, 7.82. Found: C, 67.04; H, 7.34; N, 7.83.

Acknowledgement.

Financial support for this work provided by a grant from Korea Research Foundation (KRF- 2000-015-DP0252), Korea.

REFERENCES AND NOTES

P. Delair, E. Brot, A. Kanazawa and A. E. Green, J. Org. Chem., 64, 1383 (1999); [b] V. M. Santander, A. B. Cue, J. G. H. Diaz, F. J. Balmis, G. Miranda, E. Urbina, J. Portilla, A. A. Plata, H. B. Zapata, V. A. Munoz and L. M. Abreu, *Rev. Invest. Biol. Univ. Guadalajara*, 1, 94 (1961).

[2a] R. E. Schwartz, J. Liesch, O. Hensens, L. Zitano,
S. Honeycutt, G. Garrity, R. A. Fromtling, J. Onishi and R. Monaghan,
J. Antibiot. 41, 1744 (1988); [b] J. H. Johnson, D. W. Phillipson and
A. D. Kahle, J. Antibiot. 42, 1184 (1989).

[3] S. G. Lee, K. H. Park and Y.-J. Yoon, *J. Heterocyclic Chem.*, **35**, 711 (1998).

[4] J. H. Kim, W. S. Lee, M. S. Yang, S. G. Lee and K.-H. Park, *Synlett*, 614 (1999).

[5] H. Yoda, H. Kitayama, W. Yamada, T. Katagiri and K. Takabe, *Tetrahedron: Asymmetry*, **4**, 1451 (1993).

[6] H. Yoda, H. Kitayama, W. Yamada, T. Katagiri and K. Takabe, *Tetrahedron: Asymmetry*, **4**, 1455 (1993).

[7] H. Yoda, T. Nakajima and K. Takabe, *Tetrahedron Lett.*, **37**, 5531 (1996).

[8] H. Yoda, T. Shimojo and K. Takabe, *Tetrahedron Lett.*, **40**, 1335 (1999).

[9] C. M. Schuch and R. A. Pilli, *Tetrahedron: Asymmetry*, **11**, 753 (2000).

[10a] Y. Ryu and G. Kim, J. Org. Chem., 60, 103 (1995);
[b] H. Yoda, Shirakawa, K. Takabe, *Tetrahedron Lett.*, 32, 3401 (1991).

[11] P. Beak and A. I. Meyers, Acc., Chem. Res., 19, 356 (1986).

[12a] M. J. Robins and J. S. Wilson, J. Am. Chem. Soc., 103, 932
(1981); [b] D. H. Barton and S. W. McCombie, J. Chem. Soc., Perkin Trans. 1, 1574 (1975); [c] D. H. Barton and R. Subramanian, J. Chem. Soc., Perkin Trans. 1, 1718 (1977).

[13a] P. Q. Huang, S. L. Wang, J. L. Ye, Y. P. Ruan, Y. Q. Huang,
H. Zheng and J. X. Gao, *Tetrahedron*, 54, 12547 (1998); [b] W. J. Koot,
R. V. Ginkel, M. Kranenburg, H. Hiemstra, S. Louwrier,
M. J. Moolenaar and W. N. Speckamp, *Tetrahedron Lett.*, 32, 401 (1991); [c] T. Ohta, S. Shiokawa, R. Sakamoto and S. Nozoe, *Tetrahedron Lett.*, 31, 7329 (1990); [d] A. Bernardi, F. Micheli,
D. Potenza, C. Scolastico and R. Villa, *Tetrahedron Lett.*, 31, 4949 (1990); [e] P. Beak and A. I. Meyers, *Acc. Chem. Res.*, 19, 3178 (1986).

[14a] B. W. Gung, Z. Zhu and R. A. Fouch, *J. Org. Chem.*, **60**, 2860 (1995);
[b] C. Chuit, R. J. P. Corriu, C. Reye and J. C. Young, *Chem. Rev.*, **93**, 1371(1993);
(c) D. D. Sternbach and W. C. L. Jamison, *Tetrahedron Lett.*, **22**, 3331 (1981).